15504997

Source:http://linkedlifedata.com/resource/pubmed/id/15504997

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0011860, umls-concept:C0030705, umls-concept:C0167117, umls-concept:C0332307, umls-concept:C0439230, umls-concept:C1280500, umls-concept:C2587213
pubmed:issue	11
pubmed:dateCreated	2004-10-26
pubmed:abstractText	This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7805975
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose, http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated, http://linkedlifedata.com/resource/pubmed/chemical/Insulin, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, http://linkedlifedata.com/resource/pubmed/chemical/Proinsulin, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonylurea Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Venoms, http://linkedlifedata.com/resource/pubmed/chemical/exenatide
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0149-5992
pubmed:author	pubmed-author:BaronAlain DAD, pubmed-author:BuseJohn BJB, pubmed-author:Exenatide-113 Clinical Study Group, pubmed-author:FinemanMark SMS, pubmed-author:HanJennyJ, pubmed-author:HenryRobert RRR, pubmed-author:KimDennis DDD
pubmed:issnType	Print
pubmed:volume	27
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2628-35
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:15504997-Adult, pubmed-meshheading:15504997-Aged, pubmed-meshheading:15504997-Blood Glucose, pubmed-meshheading:15504997-Body Weight, pubmed-meshheading:15504997-Diabetes Mellitus, Type 2, pubmed-meshheading:15504997-Dose-Response Relationship, Drug, pubmed-meshheading:15504997-Fasting, pubmed-meshheading:15504997-Female, pubmed-meshheading:15504997-Hemoglobin A, Glycosylated, pubmed-meshheading:15504997-Humans, pubmed-meshheading:15504997-Insulin, pubmed-meshheading:15504997-Male, pubmed-meshheading:15504997-Middle Aged, pubmed-meshheading:15504997-Peptides, pubmed-meshheading:15504997-Proinsulin, pubmed-meshheading:15504997-Retreatment, pubmed-meshheading:15504997-Sulfonylurea Compounds, pubmed-meshheading:15504997-Treatment Failure, pubmed-meshheading:15504997-Venoms, pubmed-meshheading:15504997-Weight Loss
pubmed:year	2004
pubmed:articleTitle	Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
pubmed:affiliation	Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study